Shots:
- BlueRock to get an option to license gene circuits emerging from the collaboration for cell therapy products in specific indications. If option exercises, the company will be responsible for conducting pre/clinical and commercialization activities for any candidates incorporating Senti Bio’s licensed gene circuits
- Senti Bio will strengthen BlueRock’s cell+gene platform by developing gene circuits and will be responsible for designing and testing cell state- and disease- specific Smart Sensors and Regulator Dials to be utilized in regenerative therapies
- The collaboration combines BlueRock’s iPSC platform technology and expertise with Senti Bio’s gene circuit technology platform
Click here to read full press release/ article | Ref: Globe Newswire | Image: Businesswire
The post Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine first appeared on PharmaShots.
